Key result
Ivabradine matches atenolol and amlodipine for anti-anginal and anti-ischemic efficacy in stable angina.
Why the study?
Heart rate reduction is pivotal in managing myocardial ischemia and stable angina, but use of common rate-slowing drugs is limited by poor tolerability.
Does ivabradine improve anti-anginal and anti-ischemic effects in patients with stable angina compared to atenolol and amlodipine?
Does ivabradine improve anti-anginal and anti-ischemic effects in patients with stable angina compared to atenolol and amlodipine?
Ivabradine is a selective If current inhibitor that provides effective and safe heart rate reduction with anti-anginal efficacy comparable to standard therapies like atenolol and amlodipine.
No takes yet. Share an insight, caveat, or question.
Supports ivabradine as potential alternative in stable angina; leaves open confirmation in randomized trials.
Andrikopoulos et al. (2006) conducted a review in stable angina. Ivabradine vs. atenolol and amlodipine was evaluated. Ivabradine, a selective If current inhibitor, demonstrated anti-anginal and anti-ischemic effects equivalent to atenolol and amlodipine in the treatment of stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: